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Abstract

DEVELOPMENT AND IMPLEMENTATION OF A TISSUE SPECIFIC MICRORNA
PREDICTION TOOL FOR IDENTIFYING TARGETS OF THE TUMOR
SUPPRESSOR MICRORNA-17-3P

A unique computational approach was undertaken to identify targets of miR-17-3p
that impart an oncogenic potential to the cells of the prostate. Utilizing this approach, we
identified insulin growth factor receptor 1 (IGF1R) as a potential target of miR-17-3p.
IGF1R imparts an oncogenic approach to the cells by helping cells escape apoptosis,
become hypertrophic and increase the production of extracellular proteases that allow cells
to detach from neighbors.
The regulation of insulin growth factor receptor 1 by human microRNA-17-3p was
evaluated using a western blot analysis of prostate cancer cell lines. Protein levels were
compared in a cell line that expressed a non-targeting control RNA and a cell line that
expressed microRNA-17-3p. The cell line that expressed the non-targeting control had
significantly higher levels of IGF1R protein than the cell line expressing more of the active
microRNA. Based on this experiment, it appears that microRNA-17-3p might regulate the
insulin growth factor receptor 1.

xi

Chapter 1:
Introduction
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The Prostate Gland

The male prostate gland is a walnut shaped exocrine gland about four centimeters
in diameter and has a mass of approximately 20 grams when fully mature. The prostate is
located inferior to the urinary bladder, and anterior to the rectum. Passing through the prostate is
the prostatic urethra. In boys, the prostate gland is very small and begins to hypertrophy as they
approach adolescence and reaches its mature size shortly after puberty. Under normal
circumstances, the prostate gland ceases to grow. In half of all men, when they reach an
approximate age of fifty, the gland begins to hypertrophy again. This results in a condition
known as benign prostatic hypertrophy (BPH). During the progression of BPH, the prostate
gland begins to compress the urethra and causes great difficulty in urination. Many men over the
age of fifty suffer from increased frequency of urination, hesitancy and urinary incontinence.
This prostate gland serves several important functions in the male genitourinary system.
Secretions of the prostate account for approximately two thirds of the fluid content of semen.
They include an alkalinic substance that counteracts the acidity of the vagina allowing sperm
cells to survive the harsh environment that they encounter on their journey to the mature ovum.
The prostate gland is composed in part of smooth muscle that contracts when stimulated
increasing the velocity of ejaculate through the urethra. During ejaculation the prostate gland
will contract and block the flow of urine into the urethra during ejaculation by closing off the
portion of the urethra coming from the urinary bladder.
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Incidence of Prostate Cancer

Cancer of the prostate gland is the second leading cause of cancer related deaths in men
in the United States [1]. In 2009, it is estimated that nearly 193,000 men were diagnosed with
cancer of the prostate gland and nearly 27,000 of them will die because of this cancer [2].
Nearly one in every six men will develop cancer of the prostate gland in his lifetime. Prostate
cancer is a significant problem in the United States not only because of the numbers of men
affected but also the cost of treatment of the disease is staggering.
The development of cancer of the prostate gland is influenced by a milieu of factors,
including heredity, race, age, diet, physical activity, sexual factors and obesity [3]. Age is an
important risk factor that affects the likelihood of contracting the disease. As a man ages, his risk
of developing prostate cancer increases. The incidence of prostate cancer peaks around the age
of 70 and begins to decline slightly [4]. The mean age of death of a man is approximately 76
years [4]. Figure 1-1 displays the incidence of prostate cancer per 100,000 patients broken down
by age, the data for the figure was obtained from the National Cancer Institute Surveillance
Epidemiology and End Results database. Another important risk factor that affects the
development of prostate cancer is the race of the patient. Incidences of prostate cancer are
significantly higher for an African-American than they are for a white male. African- American
men have a higher incidence of prostate cancer at every age than their white counterparts [4] .
The non-age adjusted incidence of prostate cancer for men in the United States is 268 out of
every 100,000 men.
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Figure 1-1: Incidences of prostate cancer vary with the age of the patient
The incidence of prostate cancer varies with the age of the patient. Cancer of the prostate gland is
exceedingly rare in men under the age of 50. As a man continues to age, the incidence of prostate
cancer begins to increase dramatically and peaks at approximately 70 years of age [4].
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Figure 1-1: Incidences of prostate cancer vary with the age of the patient
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Caucasian males suffer a lower than average incidence of prostate cancer at a rate of 251
men diagnosed for every 100,000. African-Americans have a much higher incidence of prostate
cancer, 385 out of every 100,000 men will suffer from cancer of the prostate gland. Figure 1-2
shows the overall incidence of prostate cancer broken down by age and race [4].
The incidences of prostate cancer have experienced dramatic fluctuations in rates of
disease diagnosis. The non-age adjusted rate of incidence per 100,000 persons is plotted for each
year from 1975 – 2006 in Figure 1-3. From 1975 to 1994 the diagnosis of prostate cancer
increased significantly. This increase in diagnosis of the disease is in part because the average
life span of Americans has increased and as previously mentioned men suffer from an increased
risk as they age. Other factors that may have lead to an increased rate of diagnosis are an
increased awareness of the disease and an increased availability of diagnostic techniques that
enable physicians to more easily detect the presence of a diseased prostate gland [5]. In 1986,
the food and drug administration (FDA) approved the use of the prostate specific antigen (PSA)
test to monitor the progression of cancer. In 1994, the FDA extended the utility of PSA analysis,
allowing physicians to utilize the level of PSA in the blood as a tool for the diagnosis of prostate
cancer. Prior to approval of the PSA screening tool, physicians were limited to diagnosing
prostate disorders by digital rectal examination of the gland.
Digital examination of the prostate gland is less effective than PSA for detection of
tumors [6]. In a multi-centered comparison of digital examination to serum levels of prostate
specific antigen, it was shown that the serum PSA level has a 32% positive predictive value of
diagnosing cancer of the prostate. While the digital rectal examination, only has a positive
predictive value of 21%. If the two methods are utilized
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Figure 1-2: Incidences of prostate cancer vary by age and race
Cancer of the prostate gland is more common in men around the age of 70 than at any other age.
For each age group, an African-American male is much more likely to get cancer of the prostate
than his white counterpart [4].
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Figure 1-2: Incidences of prostate cancer vary by age and race
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Figure 1-3: Trends in prostate cancer diagnosis
In 1975, approximately 600 of every 100,000 men without regard to their age were diagnosed
with prostate cancer. In the middle part of the 1980’s, the numbers of persons diagnosed with
prostate cancer began to grow exponentially. It is hypothesized that the increase in diagnosis of
patients with the disease is a result of an increase in the average life span, an increased awareness
of the disease, and the advent of the PSA screening tool [6]. Even though it was not officially
endorsed by the FDA, it is thought that many physicians were using the PSA level as a method to
screen for potential tumors [5].
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Figure 1-3: Trends in prostate cancer diagnosis
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simultaneously, the positive predictive value increases substantially to nearly 78%.

The role of genes in prostate tumorigenesis

Tumors of the prostate gland are highly heterogeneous clinically and histologically[7].
Despite the heterogeneity of the tumors, it has been noted that several genes may play a role in
the development of prostate cancer and tumorigenesis. Highly metastatic androgen independent
tumors were found to exhibit point mutations in the androgen receptor approximately 50% of the
time [8]. Testosterone binds to the androgen receptor and stimulates transcription of the
androgen responsive genes. Genes regulated by this manner cause the cells of the prostate to
grow. Androgen independence has long been suspected to play a role in oncogenesis of the
prostate.
There are many other genes that are suspected to play a part in tumorigenesis. A recent
study that attempted to identify a set of biomarkers to diagnose and stage tumors of the prostate
found several genes to be differentially regulated in prostate cancer [9]. Table 1-1 highlights
some of the most differentially regulated genes identified. Clearly, many genes are thought to
play a role in the development of prostate cancer through either point mutations that inactivate
the gene or through functional dysregulation.
It was recently discovered that there exist a novel class of small RNA elements that play a
large role in gene regulation by blocking translation or marking the transcript for degradation
[10]. These small RNAs are better known as microRNAs (miRNAs, miRs).

11

Table 1-1: Genes predicted to regulate tumorigenesis of the prostate

Genes that are differentially regulated between normal prostate cells and cancerous cells of the
prostate gland [9]. The function of the genes was inferred by examining the information
contained in the Information Hyperlinked over Proteins database [11]. The chromosomal
location of each gene was examined in order to identify potential genes that lie in regions of the
chromosome with a known loss of heterozygoisty involved in prostate tumorigenesis.
Chromosomal locations were determined using the Entrez cytogenetic band information from the
GeneCards resource [12]. Each of the genes listed in this table are suspected to play a role in the
development or progression of prostate cancer.
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Table 1-1: Genes predicted to regulate tumorigenesis of the prostate
Gene
Symbol

Gene Name

Function

Chromosome

IGFBP-5

Insulin Like Growth
Factor Binding Protein 5

Binds to insulin like growth factors
2q33-36[13]
and modulates cell growth;
upregulated in metastatic cancer of the
prostate

FAT

FAT Tumor Suppressor
Homolog

Cadherin related tumor suppressor

4q35 [13]

RAB5A

RAS related protein 5 B

Member of the RAS oncogene family;
regulates vesicular trafficking

3p24-22 [13]

MTA1

Metastasis associated
protein 1

Histone deacteylase inhibitor

14q32.3 [13]

MYBL2

v-myb myeloblastosis viral Transcription factor involved in cell
oncogene homolog
cycle progression
(avian)-like 2

20q13.1 [13]

HPN

Hepsin

Cell growth inhibitor

19q11-13.2
[13]

PIM1

Pim-1 oncogene

Proto-oncogene

6p21.2 [13]

Serine/ threonine protein kinase
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Discovery of microRNA and their role in development and disease

MicroRNA molecules are short, endogenous molecules that play very important roles in
gene regulation by modulating protein levels in the cell [14]. It appears that microRNAs bind to
complementary sequences in the target gene and repress protein translation or mark the protein
for degradation. First discovered in 1993 in C. elegans as temporal regulators of worm
development, microRNAs have been found to be ubiquitous in eukaryotes[15]. The Sanger
microRNA database was created in 2002 with a list of 218 microRNAs obtained from direct
submission by researchers [16]. In September 2009, version 14.0 was released with a total of
10,883 unique microRNA sequences in a variety of organisms. The Sanger microRNA
repository currently lists 772 human microRNA molecules. It is hypothesized that there are
many other microRNAs that have yet to be located in the human genome. miRNAs are involved
in numerous cellular functions and have been shown to be involved in many critical and diverse
cellular processes from cellular differentiation, viral defense, and regulation of cellular signaling
networks [17]. Researchers have just begun to unravel the functions of a few microRNA
molecules in everyday cellular processes and disease progression. There remain a large number
of miRs that have yet to be explored.
Mature microRNAs are approximately twenty two nucleotides in length and are thought
to bind to the 3’ untranslated region of the messenger RNA and guide the RNA induced
silencing complex to the message. After the microRNA binds to the mRNA, the mRNA is
translationally repressed or degraded [16]. Elucidating the exact role of microRNA regulation
and dysfunction in disease continues to be a complicated undertaking.
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microRNA role in cancer progression

microRNA molecules play a role in the development of several forms of human cancer
including breast, prostate, lung, thyroid, and B cell lymphoma [18]. Several microRNAs
regulate critical biological processes such as cell proliferation control, cell hypertrophy,
apoptosis, cell survival and insulin secretion [19]. As cancer is the end result of uncontrolled
proliferation and survival of damaged cells, these biological functions have previously been
shown to contribute to the development and progression of cancer.
MicroRNAs can contribute to oncogenesis by functioning as oncomiRs or tumor
suppressors. miRs that regulate genes controlling cell proliferation, hypertrophy, and
angiogenesis are often considered to function as tumor suppressors [20]. Loss or deregulation of
tumor suppressing microRNAs imparts a growth or survival advantage to the cells, resulting in
the formation of tumors. miRs that regulate apoptosis are often considered oncomiRs, increased
levels of oncogenic microRNAs will impart an advantage to the cells and lead to increased
tumor formation.
microRNA-17-3p functions as a tumor suppressor in the prostate

microRNA-17-3p has been shown to affect the tumorigencity of the prostate gland [21].
An in vitro cancer progression model system of genetically related prostate sublines showed
increasing or decreasing levels of miR17-3p that negatively correlate with the oncogenic nature
of the tissue [21]. The parental P69 cell line is a tumorgenic, non-metastatic cell that shows
relatively high levels of human microRNA-17-3p. The highly metastatic cell line, M12 showed a
two-fold decrease in the level of microRNA-17-3p. The M12 subline has been shown to contain
15

a loss of one copy of chromosome 19p-13 that resulted from an unequal translocation of
chromosome 16:19. The F6 subline is a poorly tumorigenic, non-metastatic cell line that resulted
from the micro-cell fusion techniques for restoration of the second copy of chromosome 19. The
F6 subline expresses higher levels of miR17-3p than the parental P69 (Figure 1-4). Restored
expression of miR-17-3p in the M12 cell line was shown in vitro and in vivo to reduce
tumorigencity by at least 50% [22].These experiments clearly show that microRNA-17-3p
functions as a tumor suppressor in vitro [21].
Clinical human samples derived from formalin-fixed, paraffin embedded samples
obtained after prostatectomy confirmed that levels of microRNA-17-3p decrease as
tumorigencity increases [21]. Relative levels of miR-17-3p were significantly decreased in
regions of the prostate that were cancerous. Further, it has been shown that levels of miR17-3p
decrease as the Gleason score of the tumor increases. Essential to understanding the role of the
microRNA in the tissue is the identification of putative targets of the microRNA. Previous
studies show that miR17-3p regulates expression of vimentin [22].

Role of intermediate filament proteins in cancer

Intermediate filaments are fibrous proteins found within the cytoplasm and nucleoplasm
of most eukaryotic cells [23]. Some intermediate filaments like vimentin tend to be peri-nuclear
localized and form a cage around nucleus extending to the surface of the cell. It has long been
known that intermediate filaments are essential for the internal integrity of the cell and the shape
of the cell. However, it has become clear in the past few years, that intermediate filament
proteins are dynamic molecules involved in many regulatory functions.
16

Figure 1-4: Genetically related prostate cancer progression cell lines
Unique genetically related cell line, derived from injection of prostate cancer cells into nude,
athymic mice [24]. The parental cell line (P69) is a slightly tumorigenic, non-metastatic cancer
cell line. After several rounds of injection, the cells became highly tumorigenic and metastatic
(M12). The subline was noted to exhibit an unequal translocation of chromosome 16:19.
Microcell fusion techniques were used to inject the missing region of chromosome 19 into the
M12 subline [25]. After insertion of the missing region of chromosome 19, the subline became
less tumorigenic and non-metastatic (F6).
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Figure 1-4: Genetically related prostate cancer progression cell lines

Name of cell

Description

subline
P69

Parental cell line, tumorigenic and

Relative levels

Relative levels

of vimentin

of miR-17-3p

0.09

0.0032

0.24

0.0018

0.01

0.0038

non-metastatic
M12

Highly tumorigenic and metastatic
subline; Ch 16:19 translocation

F6

Restored chromosome 19; nontumorigenic
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Vimentin is an intermediate filament protein that is produced by the Vimentin gene on
chromosome 10p13 [12]. The protein is 466 aminoacids in length and has a mass of 53.6 kDa.
Vimentin has been shown to be differentially regulated in prostate cancer cell lines. Previous
studies have demonstrated that tumors containing higher levels of vimentin are more motile and
invasive [26]. The highly metastatic M12 cell subline has significantly higher levels of vimentin
compared to the less tumorigenic P69 and F6 cell lines [22]. Likewise, vimentin expression was
significantly increased in highly invasive, androgen insensitive cell lines (LnCap CL1) [26].
Subcutaneous injection of tumor cells into nude, athymic, male mice revealed that the
M12 subline is highly tumorigenic in vivo [22]. The mice injected with the M12 subline all
formed tumors within nine to fifteen days. The F6 subline injected mice failed to grow a tumor
or grew very small tumors 120 days post-injection. As the levels of vimentin vary among the cell
lines, the effect of vimentin on tumor growth was investigated by injecting mice with M12s
along with a vimentin small hairpin RNA (shRNA). The mice injected with the M12 variant
expressing a vimentin shRNA (M12 +siVim). In the mice injected with the M12 + siVim variant
the size of the tumors was greatly reduced compared to the M12 subline alone. To investigate the
role of human microRNA17-3p on tumor formation in nude, athymic mice, the animals were
injected with an M12 variant subline containing a microRNA-17-3p over expression vector [21].
Tumor formation was reduced but not to the same degree as the mice containing tumors with the
shRNA for vimentin. It seems that miR-17-3p may regulate some protein(s) that infers a slight
advantage to the cells. In order to further understand the role of miR-17-3p in the prostate, one
must identify these other putative targets of the miR, in addition to vimentin.
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Biogenesis of microRNA molecules

Essential to understanding the role miRNAs play in cellular processes is the identification
of their putative targets. The past decade has seen a large increase in the numbers of
computational methods for the identification of miR/ gene targets. The methods employed by the
various computational tools are diverse. They range from simple string based methods to more
complicated markov models. Before understanding the techniques of microRNA target
prediction, one must understand the biogenesis of microRNA and the types of interactions
between miRNAs and their target genes.
miRNA genes can be part of a polycistronic transcript of 2- 7 microRNA genes under the
control of a common transcriptional regulator or can be excised from introns of protein coding
genes [27]. MicroRNAs in animals are created using a two step process [28]. Figure 1-5
illustrates the step wise biogenesis of the microRNA molecule. The first step involves
transcription of a several hundered nucleotide in length transcript that is called the pri-miRNA
by RNA pol II or RNA pol III. The pri-miRNA is processed into a smaller structure of
approximately 70 nucleotides (pre-miRNA) in length while in the nucleus. The processing is
accomplished by a complex of several proteins, the most important being Drosha [29]. The premiRNA has a characteristic stem loop shape and is exported from the nucleus by a complex of
Exportin 5 of Ran-GTP [30]. Once in the cytoplasm, the pre-miRNA undergoes the second
phase of processing, where it is processed by the enzyme Dicer into its mature form that is 22
nucleotides in length [31].

20

Figure 1-5: Biogenesis of microRNA

1. MicroRNA molecules are transcribed from introns of protein coding genes or are a part of
a polycistronic transcript by RNA polymerase II or RNA polymerase III. The pri-miRNA
is several hundred nucleotides in length and contains regions of stems and loops. [27]
2. A complex of enzymes that includes Drosha, a Rnase II enzyme, cleaves the pri-miRNA
into the shorter microRNA molecule (pre-miRNA) [27, 32].
3. The pre-miRNA has a characteristic stem loop shape and is approximately 70 nucleotides
in length [32].
4. The pre-miRNA is exported from the nucleus to the cytoplasm by the Exportin V
complex [30].
5. In the cytoplasm, the enzyme Dicer recognizes the characteristic stem loop shape of the
pre-miRNA and cleaves into the functional mature microRNA molecule [31].
6. Mature microRNAs can be generated from either the 5’ or the 3’ end of the stem loop of
the pre-miRNA [29]. The mature micrRNA is typically 22-25 nucleotides in length and
binds to the 3’ untranslated region of the mRNA transcript.
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Figure 1-5: Biogenesis of microRNA

22

Computational methods of identification of putative targets

MicroRNAs interact with their targets through sequence complementarity. In some cases,
seven complementary bases on the 5’ end of the microRNA are adequate to posttranscriptionally regulate protein levels [33]. Bases 2-7 of the microRNA seem to be critical in
order for the microRNA to be able to bind to its target. These bases are commonly referred to as
the seed region of the miRNA. Many miRNA/ target interactions exhibit 3’ compensatory loop
interactions that further stabilize the structure of the molecule. Due to the relatively short size of
microRNA molecules and the small number of complementary bases, computational prediction
of potential targets of miRNAs is very difficult [34]. Other features that complicate attempts at
computational prediction of interactions are the presence of regions of mismatches between the
microRNA and the target 3’ UTR, G:U wobbles and sequence bulges [35]. Table 1-2 lists the
details of some of the most commonly utilized tools for prediction of microRNA targets.

The miRanda algorithm

One of the earliest attempts to identify potential putative targets of microRNAs was the
development of the miRanda algorithm [36]. The algorithm employed by miRanda utilizes a two
step process. First, it inputs the sequence of the microRNA and compares it to the 3’ untranslated
region of all genes in the input file. Seed region base complementarity is given a higher reward
than complementarity of bases on the 3’ end of the microRNA molecule. The reason for this
reward is because it is generally thought that the seed region interactions are critical to the
ability of a miRNA to repress protein translation. The program evaluates each potential match
based on base sequence complementarity. Complementary sequences that exceed a pre-defined
23

Table 1-2: Common MicroRNA/ Target Prediction Tools
Computational methods to identify potential putative targets of microRNA are essential to
elucidation of their role in the biological realm. We list some of the most commonly cited
computational tools in existence, the world wide web address of each tool and the number of
times each prediction tool has been cited in microRNA related literature as of September 2009.
Often the number of citations is used to indicate popularity of a program. Utilizing this metric, it
appears that PicTar and TargetScan are the most commonly utilized tools for microRNA target
identification.
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Table 1-2: Common MicroRNA/ Target Prediction Tools

Tool

Web Location

Diana
MicroT 3.0

http://diana.cslab.ece.ntua.gr/microT/

Miranda

http://www.microrna.org/microrna/home.do

PicTar

http://pictar.med-berlin.de/

TargetScan

http://www.targetscan.org/

RNA 22

http://cbcsrv.watson.ibm.com/rna22.html

Type of Tool
Precompiled List
Open source and
precompiled list
Precompiled List
Open source and
precompiled list
Precompiled List
and webserver

.
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Times
Cited

Reference

Not
Available

[18]

30

[36]

595

[37]

1081

[38]

114

[39]

threshold set by the user will enter the second phase of evaluation. Potential matches will be
evaluated for thermodynamic stability using the RNAlib module of the Vienna RNA package
[40].

TargetScan

TargetScan employs an algorithm that scans the 3’ UTR of possible targets for the
presence of one of three types of canonical seed region interactions [38]. The most favorable and
highly scored interaction results from complementarity of positions 2-8 of the microRNA and
the presence of an adenine nucleotide at the far 3’ end of the potential binding site in the UTR.
The second most favorable interactions come from binding of bases 2-7 of the microRNA, along
with an adenine residue at the end of the bound region of the target or binding of bases 2-8 of
the microRNA to the target. The least favorable target considered to be possible utilizing the
TargetScan algorithm is complementarity of bases 2-7 of the microRNA and target UTR.

PicTar

PicTar is a computational tool for the prediction of microRNA targets that not only
employs seed region interactions, but also ensures evolutionary conservation and secondary
structure stability [37]. PicTar accepts as input two files; the first contains a multiple sequence
alignment of the 3’ UTR of related species and a second file containing the microRNA
sequences of the researcher. The algorithm employed by PicTar searches the multiple sequence
alignment for sequences that would adhere to the seed region by strictly following the Watson-
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Crick base pairing rules. The algorithm allows the seven bases of the seed region to begin at
either position one or two of the microRNA. Potential microRNA binding sites are filtered by
free energy of heteroduplex formation. Binding sites that have a free energy lower than the
desired threshold are retained and further analyzed. If the potential binding site exists in a region
that is completely conserved across several species, the binding site is considered to be valid and
a hidden markov model maximum likelihood fit score is calculated. Potential binding sites are
ranked based on their score. Higher scores represent binding sites that are more likely.

Diana MicroT 3.0

Diana microT 3.0 utilizes sequence similarity, free energy of heteroduplex formation and
to a lesser degree multiple species conservation to identify potential binding sites [18]. The
algorithm employed by Diana, pulls out the first nine nucleotides (driver sequence) and uses a
sliding window approach to scan the 3’ UTR of the gene for sequences that are complementary
to the driver sequence in at least six consecutive nucleotides. The program allows a single G:U
wobble, as long as there are at least six Watson-Crick base pairs in the alignment.
Potential binding sites with less than seven Watson- Crick pairs are further evaluated
using the free energy value of heteroduplex formation using the RNA hybrid algorithm [41]. The
first step of filtration is accomplished by passing the actual microRNA sequence and the
potential binding site to the RNA hybrid program. Following the calculation of the actual binding
energy, a hypothetical binding energy is calculated by estimating the binding energy of the
perfectly complemented sequence to the microRNA. If the ratio of theoretical to hypothetical
binding energies is greater than 0.74, the sequence is identified as a potential “miRNA
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recognition element (MRE)” or a predicted binding site [18].
Sequences of multiple species are examined to determine if the potential MRE is present
in other species to identify sequences that are conserved in multiple species [18]. It is
hypothesized that sequences that have been conserved though out millions of years of evolution
possess functional significance. Species that are examined include humans, rats, mice, dogs and
zebrafish. A conservation score is generated that is equal to the number of species that contain
the individual MRE. The conservation score and the binding score are combined into a
microRNA target gene score (miTG). Potential binding sites are ranked by their miTG scores.

RNA22

RNA22 is a pattern based method that relies on information inherent in the nucleotide
sequences of the microRNA molecule [39]. RNA22 uses the Teiresias algorithm to identify
patterns in the sequences of microRNA molecules from reference species in the RFAM database
[42, 43]. Following pattern identification, the UTRs of the genes of interest are scanned for the
presence of “target islands” that possess at least one of the patterns identified in the pattern
matching step of the algorithm. Target islands are matched to candidate microRNA molecules
based on sequence complementarity. A score, based on the number of Watson-Crick base pairs in
the heteroduplex, is generated. Potential binding sites that exceed a given threshold are returned
to the user.
Project Objectives
The computational identification of putative targets of microRNA is critical to
understanding the role a given miR plays in development and disease. Presumably, programs that
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include multiple features of miR/ target interactions will be more accurate than programs that
include fewer features. In practical terms, accuracy is defined as the ability of a method to
identify true interactions and reduce the number of false predictions. Researchers desire to
identify the greatest number of true interactions at the lowest cost of investigation in terms of
fiscal cost and manpower. With so many computational methods in existence, researchers must
understand the features, advantages, and benefits of each of the programs.
In order to fully understand the mechanism of tumorigenesis, this project seeks to identify
putative targets of miR-17-3p using a combination of computational and traditional wet-lab
techniques. Prior to the utilization of previously published microRNA prediction tools, all tools
were evaluated using a standardized set of proven microRNA and gene targets to measure the
accuracy of the programs. As part of this project, we designed and implemented a comprehensive
microRNA annotation and prediction interface (MAPI) that increased the accuracy of current
programs. MAPI was utilized to identify potential targets of miR-17-3p that are expressed in the
prostate gland and involved in tumorigenesis. Utilizing wet-lab techniques, the targets were
evaluated in a cancer cell progression model using western blot analysis of target protein levels.
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Specific Project Aims



Evaluate current computational microRNA prediction tools to determine which program or
combination of programs offer users the best balance of sensitivity and specificity.



Design and implement a comprehensive computational interface that increases the
effectiveness of previously published programs by filtering irrelevant targets
o Include transcriptional profiles for various tissues and disease states



Use the computational interface to identify potential targets of human microRNA-17-3p that
potentially impart an oncogenic advantage to the cells when overexpressed.



Utilizing a cancer cell progression model, verify that the levels of the predicted target of
microRNA-17-3p are more abundant in the highly tumorigenic and metastatic M12 cell line.
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Chapter 2
Evaluation of computational methods of microRNA target identification
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Methodology to compare microRNA prediction programs

The past decade has seen a large increase in the attempt to determine the exact
role microRNAs play in the maintenance of health and the development of disease. To
understand the role of a given microRNA in human disease, a researcher must first identify its
putatitive targets. Many computational tools/ programs have been developed to assist
researchers in the prediction of microRNA target gene interactions. The methods employed by
the various computational programs vary greatly. This project seeks to evaluate the sensitivity of
each method along with determining the total number of predictions. This work compares the
predicted targets of Diana MicroT, Miranda, Pictar, TargetScan, and RNA22 utilizing a set of
microRNA molecules that are shared by all methods [18, 37-39, 44]. This work only evaluates
the performance of the various programs to predict human microRNA gene interactions as most
researchers are interested in determining the role microRNA play in the development of human
disease.
A previous study conducted by Sethupathy, Megraw, and Hatzigeorgiou in 2006
evaluated the sensitivity of various target identification programs using a benchmarking dataset
of targets from the Tarbase database for experimentally proven microRNA gene target pairs [45,
46]. At the time of that publication, there were only 84 such targets for 32 microRNAs that had
been proven. In the past three years, both the number of putative targets for microRNAs and the
number of prediction programs have increased dramatically. It is reasonable to suspect that with
the increase of available data and more advanced methods that the former conclusions are no
longer valid.
Researchers found that the single best tool in existence in 2006 was Miranda and that the
best sensitivity could be achieved by overlapping the predictions from every program available
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[45]. However, biologists cannot search through the number of predictions generated by
overlapping the predicted targets. Scientists often attempt to enrich the number of true
interactions by considering only microRNA targets that have been predicted by more than one
method. The previous study recommended that in order to balance the needs of researchers to
maintain a high level of sensitivity and allow researchers to search through a lower number of
potential targets, only targets predicted by PicTar and TargetScanS be considered [37, 38].

Compilation of Predictions

Predictions for DIANA-MicroT 3.0 were downloaded in a pre-compiled tab delimited
text file from their webserver, which can be found at the URL listed in Table 1. Human
microRNAs that target a unique gene with a miTG score of at least 1.0 were included in our set
of predicted targets. Multiple interactions per gene, if possible, were collapsed into a single
predicted pairing. PicTar predictions were compiled using a PERL script that downloaded all
predicted targets for each human microRNA that was available on the PicTar server as of July 5,
2009. TargetScan 5.1 human data was downloaded from the TargetScan server using the
predicted conserved targets file. Precompiled predictions were downloaded from Miranda using
the web address specified in table 1 and downloading the human miRNA target site predictions
file. RNA 22 predictions were assembled using the precompiled data file for only the 3’-UTR
region.
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Development of a standardized microRNA/ target comparison set

In order to measure the sensitivity of each computational program, we assembled a set of
microRNA/ target interactions that have been experimentally proven. Tarbase and miRecords are
web based resources where researchers report microRNA/ gene pairs that have been
experimentally validated [46, 47]. By combining the two datasets and eliminating multiple
entries, we developed a comprehensive list of proven human microRNA/ gene interactions.
MicroRNAs have been shown to bind to more than one site on a given target gene, in this study
we eliminated such multiple binding sites and considered the pairing as a single predicted
interaction. We compiled a list of 826 experimentally verified microRNA targets.

Sensitivity Analysis

As the number of microRNAs vary slightly between tools, it was necessary to create a
standard set of microRNA molecules that could be used to accurately compare each tool. We
intersected the microRNA identifiers from each tool and found that only 139 microRNAs were
shared among all of the tools that we compared in this study. Of these 139 common microRNAs,
we found that there were 451 unique interactions. These interactions were the only predictions
that we utilized in the sensitivity analysis.
Each prediction method previously described was compared to the standardized
comparison target set in order to determine how well each tool performed. Of particular interest
to microRNA researchers is the sensitivity of each tool. Figure 2-1 shows the formula for
derivation of sensitivity. Sensitivity evaluates the proportion of experimentally proven
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interactions that are correctly identified by the evaluated program. Successful tools will ideally
be able to correctly identify a majority of the experimentally verified microRNA targets.
Following individual program analysis, we evaluated various combinations of tools to
determine if there exists an ideal combination of computational tools that can identify most
microRNA targets. In order to accomplish this objective, each set of microRNA/ target
predictions was pair wise intersected with all other tools in an effort to determine the
sensitivities of each possible combination of tools. Likewise, sets of predictions for each tool
were overlapped (unioned) in pair wise fashion with every other tool in an attempt to increase
the sensitivity. We illustrate the concept of mathematical union and intersection in Figure 2-2.
Many researchers base their decision on which microRNA tool to use based solely on the
sensitivity of the various tools. However, one could theoretically predict every gene to be a
target of each microRNA and achieve a sensitivity of 100%. Specificity measures the proportion
of incorrect or negative interactions that are correctly identified. It is difficult to measure the
specificity of a microRNA target prediction tool, as there is not a comprehensive database that
tracks negative experimental results. Therefore, as a surrogate for specificity, in this study we
compared the performance of each tool by calculating the total number of predictions. The
numbers of predictions are only the predicted pairings that originate from our set of 139
common microRNA molecules.
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Figure 2-1: Sensitivity Analysis
Details the analysis process utilized to measure sensitivity of each microRNA prediction tool
and combination of prediction tools.

36

Figure 2-1: Sensitivity Analysis
Sensitivity is defined as:
Number of true positive interactions
(Number of true positive interactions + number of false negative interactions)
True Positive Interaction

False Negative Interaction

Interaction predicted by the tool or combination of
tools and is found to be in our standardized list of
experimentally proven targets
A member of the standardized list of experimentally
proven interactions that is not correctly predicted by
the tool or combination of tools.
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Figure 2-2: Venn diagram of the union and intersection of the PicTar and Diana MicroT 3.0
datasets

Targets were predicted for the 139 microRNAs common to all tools. Diana MicroT 3.0 predicts
approximately 373,000 total interactions among our standardized list of microRNAs. PicTar
predicts slightly less than 49,000 interactions among the 139 microRNAs in common to all
prediction programs compared. If a researcher only considers the microRNA targets predicted by
both programs (targets in the intersection of the two tools), the number of potential targets is
reduced to approximately 29,000 possible targets. Sensitivity is increased by taking the union of
the two sets of predicted targets. The union of the datasets includes any targeted predicted by
either Diana MicroT3.0 or PicTar. The union of the two datasets predicts nearly 383,000 possible
targets.
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Figure 2-2: Venn diagram of the union and intersection of the PicTar and Diana MicroT 3.0
datasets

Diana
MicroT
PicTar
3.0
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Findings

There exist many computational methods for prediction of microRNA/ gene interactions
in humans. In this study, we compared five commonly used microRNA prediction tools. A list
of tools compared in this study, along with the web location, method of data acquisition, and the
number of citations referencing that tool are listed in Table 1-1.
In Table 2-1, we show the sensitivity and the number of total predictions generated using
our list of common microRNAs for each tool and combination of tools. This analysis found that
the single best performing microRNA/ gene prediction tool is DIANA-MicroT 3.0 [18].
Although this program has been around for several years, version 3.0 was first described in July
2009 and was included in this analysis because of their self reported 66% precision rate. Figure
2-3 plots the calculated sensitivity versus the total number of predictions for each of the tools.
The algorithm utilized by DIANA-MicroT 3.0 considers several types of seed region binding,
cross species conservation, and thermodynamic stability of seed region interactions. Potential
binding sites are given a microRNA target gene score (miTG) which reflects the relative strength
of the prediction. Our analysis found that DIANA-MicroT 3.0 was able to achieve a sensitivity
rating of nearly 46%. However, to accomplish this level of sensitivity, the program predicted
over 370,000 microRNA/ gene pairings. Users can decrease the total number of predictions by
increasing the minimum miTG score.
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Table 2-1: Sensitivity Analysis of each Prediction Tool and Combination of Prediction Tools

Comparison of the sensitivity and total number of predictions for each microRNA target
prediction tool and combinations of the intersections and unions of various tools. Using this
analysis it is clear that to achieve the best sensitivity, a researcher needs to combine all of the
predictions of as many tools as possible. However, in order to achieve that level of precision, a
researcher will need to look through nearly 3800 predictions per microRNA. The single best tool
is Diana MicroT 3.0 which achieves a sensitivity of nearly 46% while predicting less than 2800
possible interactions per microRNA [18, 37-39, 44]. Programs that achieve the highest
sensitivity are able to more correctly identify true interactions.
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Table 2-1: Sensitivity Analysis of each Prediction Tool and Combination of Prediction Tools
Total
number of
Tool
Sensitivity
predictions
Diana
Miranda
PicTar
RNA22
Target Scan
Intersections of tools
Target Scan/ Miranda Intersection
Diana/ PicTar Intersection
Miranda/ TargetScan Intersection
Diana/ Miranda Intersection
Miranda/ PicTar Intersection
Diana/ TargetScan Intersection
RNA22 / TargetScan Intersection
PicTar/ TargetScan Intersection
Miranda/ RNA22 Intersection
PicTar/ RNA22 Intersection
Unions of tools
Diana/ Miranda Union
Diana/ PicTar Union
Miranda/ TargetScan Union
Diana/ RNA22 Union
Miranda/ PicTar Union
Diana/ TargetScan Union
RNA22/ TargetScan Union
PictTar/ TargetScan Union
Miranda/ RNA22 Union
PicTar/ RNA22 Union
Union of all tools
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45.9
4.2
24.4
10.8
21.4

372530
14612
48948
85481
209151

2.9
18.3
2.2
8.3
1.7
17.1
2.5
9.7
1
4.7

4327
28617
3283
30080
843
131114
13659
14068
1089
4800

47.3
52
23.4
48.5
26.9
50.2
29.7
36.1
14.1
30.5
56.9

382815
392861
220480
427931
62717
450567
280973
244031
99004
129629
528237

Figure 2-3: Scatterplot Comparison of MicroRNA Prediction Tools
The sensitivity versus the total number of predictions for individual tools and the combinations
of Pictar and Diana MicroT 3.0 was plotted [14, 37-39, 47]. Our analysis proves that the best
method to identify the greatest number of experimentally proven targets is to consider any target
predicted by any microRNA target prediction tool. However, using this approach researchers
will have to search through an average of 3600 targets per microRNA. This is a daunting task
that can only be accomplished by a large research group with abundant financial resources.
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Figure 2-3: Scatterplot Comparison of MicroRNA Prediction Tools
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The sensitivity of predictions of DIANA-MicroT 3.0 can be increased by adding the
predictions of any other tool to the predictions made by DIANA. The union of PicTar and
DIANA together are able to achieve over 50% sensitivity [18, 37]. Due to significant overlap of
the predicted targets in these two datasets, this increased sensitivity can be accomplished with
only a five percent increase in the total number of predictions. The best sensitivity can be
achieved by compiling all of the predicted targets of each of the target prediction programs into
a single list. This results in a near 57% sensitivity value, but the total number of predictions
would be over a half million or nearly 3600 targets per microRNA molecule. It does not make
biological sense that a single microRNA would target over one tenth of the human genome.
Previous groups have suggested that it is more biologically plausible to suspect that each
microRNA may target nearly 500 genes [12].
PicTar searches a multiple sequence alignment of RNA sequences for perfect seed
region binding of the first seven nucleotides beginning at position 1 or 2 of the 5’ end of the
mature microRNA sequence [37]. The PicTar algorithm filters out potential targets that do not
meet a minimal free energy cutoff using the RNA Hybrid program [48]. In addition to seed
region binding and thermodynamic stability, PicTar filters out potential false positive predictions
by ensuring that the UTR sequence is conserved across multiple vertebrate species. According to
our analysis, PicTar is able to achieve a sensitivity score of nearly 25%. The number of
potential targets predicted by PicTar is far less than the number of targets predicted by other
methods. Presumably, this would make PicTar one of the more specific programs available for
use by microRNA researchers.
As previously mentioned, biomedical researchers often intersect the predicted targets of
multiple programs in an attempt to enrich the number of true interactions in their data set.
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Recently, the validity of this approach was questioned [49]. Our analysis finds that the
sensitivity of the methods is greatly decreased by intersecting combinations of predicted targets.
Diana MicroT and Pictar were able to achieve 52% sensitivity when the sets of data were
overlapped and unioned together. When the list of potential targets was intersected, and only
targets predicted by both methods were considered, the sensitivity was reduced to 18%.
This analysis demonstrates the complexity associated with predicting microRNA targets.
Researchers seeking to study the effects of a given microRNA on development or disease face a
difficult task. Currently, the single best tool can only identify approximately half of the
experimentally proven interactions. This finding highlights the necessity to develop newer, more
accurate methods of target identification or develop methods that reduce the number of
predictions associated with overlapping multiple tools.
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Chapter 3
Development of the MicroRNA Annotation and Prediction Interface
(MAPI)
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Features of MAPI

Cancer is a highly, heterozygous disease resulting from a combination of genetic and
epigenetic factors. Even though cancers are highly individual, it has been known for quite some
time that each cancer has a unique molecular signature or molecular portrait [50]. This portrait of
each cancer profiles the highly variable nature of gene expression as measured by the DNA
microarray. Recent work has shown that expression profiles of microRNAs are also highly
variable in various forms of human cancer [51]. miRNA expression profiles can be used to detect
developmental lineages and differentiate between various stages of the disease. As microRNAs
regulate gene translation, there exist tissue specific differences among genetic profiles in various
tissues/ diseases and there exist tissue specific differences among microRNA expression levels.
Thus, it is reasonable to assume that one could integrate these sources of information and yield a
more accurate computational method for the prediction of targets of microRNA.
The microRNA annotation and prediction interface (MAPI) is a comprehensive tool that
integrates multiple information sources into a single easy to use interface. MAPI was built using
the MySQL open source database, PERL, and an html front end user interface and provides a
centralized resource that includes several of the most highly referenced computational prediction
programs. The database allows end users the flexibility to choose from any of the computational
tools included in the program or choose from one of several combinations of programs that offer
the user the highest sensitivity and specificity.
The greatest strength of MAPI is the ability to filter predicted targets based on numerous
biological parameters, allowing users to retain a high level of sensitivity and decrease the overall
number of predictions per microRNA. MAPI allows users to select a tissue of interest and search
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for targets of a specific microRNA or search for a microRNA(s) that target a gene of interest.
The program searches for microRNAs and gene targets that are co-expressed in the tissue of
interest.

MicroRNA annotation

All microRNA sequences were downloaded from miRBase. miRBase is a searchable,
annotated database of microRNA resources [16]. miRBase version 14.0 was used for compilation
of microRNA attributes. Data was downloaded using the FTP site of the resource at
ftp://mirbase.org/pub/mirbase/CURRENT/. The files downloaded included the file containing the
precursor microRNA ID and sequence named hairpin.fa.gz, the file containing the mature
microRNA ID and sequence named mature.fa.gz, and the file that contained the alternative
microRNA from the 3’ end of the precursor named maturestar.fa.gz. All files were decompressed
using the unix operating system and a PERL script was written to extract the name and sequence
of each human microRNA . Hairpin microRNA molecules were mapped to a chromosomal
location using the hsa.gff file found in the genomes directory of the above ftp site. Each
microRNA precursor was linked to the appropriate mature microRNA molecule(s). In some
cases, a single precursor can give rise to two mature microRNAs. All files were assembled into
database tables and uploaded to the MAPI interface (Table 3-1 and 3-2).
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Table 3-1: Description of precursor microRNA table
The pre-miRNA table contains a list of all human precursor microRNA molecules. Information
was obtained from the Sanger microRNA repository. Each pre-miRNA is annotated to include
the chromosomal location of the precursor molecule, sequence and direction of the molecule in
reference to the chromosome [16].
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Table 3-1: Description of precursor microRNA table
Precursor microRNA Table
microRNA precursor ID
microRNA accession ID
Sequence
Chromosome
Chromosomal Start
Chromosomal End
Length of pre-miRNA
Chromosomal direction
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Table 3-2: Description of the Mature microRNA table
The mature microRNA table contains a list of all human mature microRNA molecules, their
corresponding sequence, the identifier of the associated the pre-miRNA, and the chromosome
that gives rise to the mature miRNA.
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Table 3-2: Description of the Mature microRNA Table
Mature microRNA Table
microRNA mature ID
microRNA precursor ID mapped to mature ID
Sequence
Chromosome
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Table 3-3: Predicted targets of microRNA molecules
Each predicted interaction of a microRNA and gene are listed in the predicted targets table. The
computational tool and score generated by that method are listed in the interaction table.
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Table 3-3: Predicted targets of microRNA molecules
Predicted Targets of microRNA
microRNA mature ID
Target gene
Interaction score
Prediction tool
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Assembly of predicted targets

Potential targets were assembled for Pictar, TargetScan, RNA22, Miranda, and Diana
MicroT 3.0 [18, 36-38, 44]. The methodology described in Chapter 2 was used to compile all of
the predicted targets for each prediction tool. When applicable, multiple interactions of a
microRNA to a single gene were combined into a single interaction. A singleMySQL table was
created from the compilation of all predicted interactions (Table 3-3).

Compilation of oncogenic genes

It is well known that aberrant expression of certain genes imparts an oncogenic nature to
the cells/tissues. Through the efforts of the National Cancer Institute’s Cancer Genome Atlas,
many of the genes that have been proven to be involved in tumorigenesis
have been compiled into a single resource [52] . The Cancer Genome Atlas has assembled a list
of 386 genes that impart tumorigenicity to the tissue. A privately funded group compiled a list of
putative oncogenes, tumor suppressors and proto-oncogenes by using literature mining methods
and called the resource the Cancer Genetics Web. The two resources were combined into single
comprehensive list using a PERL script that eliminated redundancy of genes. The final list of
potential cancer causing genes was uploaded into the MAPI resource using MySQL (Table 3-4).
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Table 3-4: Genes involved in the progression of cancer
All genes shown to function as oncogenes, proto-oncogenes and tumor suppressors are listed in
the cancer related genes table. The cytogenetic band of each cancer related gene is listed with its
corresponding refseq ID.
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Table 3-4: Genes involved in the progression of cancer
Cancer related genes
Alias
Gene symbol
Cytogenetic band
Refseq ID
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Transcriptional regulation of genes

The National Center for Biotechnology Information hosts the Unigene database [53].
Unigene is a centralized, non-redundant database that organizes expressed sequence tags into
gene oriented clusters. The Unigene database was downloaded from the FTP server at
ftp://ftp.ncbi.nih.gov/repository/UniGene/. Human transcripts were extracted from the database
using a PERL script.
There are over 120,000 unique transcripts expressed by the human genome. Unigene
organizes the transcriptional information into the body site that expresses the EST, disease state,
expression level of the transcript, and the developmental state. The unigene database lists each
unique transcript and the number of times that transcript has been seen in that particular state. For
the MAPI interface, the expression level of each transcript was transformed to represent the
number of transcripts per one million. (Table 3-5).
Tissues accomplish their functional goals by regulated expression of necessary
gene products. Each tissue expresses a unique number and combination of genes. For this study,
we compared the number of unique transcripts between the normal prostate gland and the
cancerous prostate gland (Figure 3-1). When the prostate gland becomes cancerous, the number
of expressed gene products is significantly decreased. In addition to a decrease in number of the
genes expressed, the average level of expression of each gene increases as compared to the
normal gland (Table 3-6).
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Table 3-5: Tissue Specific Gene expression levels
Each unique unigene transcript is listed, along with the developmental stage/ health state
associated with each transcript and a normalized level of transcription.
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Table 3-5: Tissue Specific Gene expression levels
Gene Expression Table
Gene ID in unigene format
Type of transcription
Tissue
Expression level in transcripts per million
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Table 3-6: Comparison of gene expression in the normal and cancerous prostate gland
Utilizing data obtained from Unigene, we determined that the number of unique RNA transcripts
decreases in the cancerous prostate gland, as compared to the normal prostate. The tumorigenic
tissue expresses approximately 30% fewer genes than the non-cancerous tissues. Even though
the overall number of unique transcripts is fewer, the transcriptional level of each transcript is
higher in the cancerous tissue than the non-cancerous tissue. At least in the prostate gland, when
the gland becomes cancerous there is a significant increase in the expression level of a smaller
number of genes.
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Table 3-6: Comparison of gene expression in the normal and cancerous prostate gland

Condition Number of

Average

Minimum

Maximum

transcripts

expression

expression

expression

Cancer

14505

68.94

9.6

8040.8

Normal

22087

45.26

5.2

5974.8
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Figure 3-1: Unique transcripts in the normal and cancerous prostate gland
The number of unique transcripts in the normal and cancerous prostate gland were extracted and
compared to one another. The normal prostate gland expresses approximately 23,000 unique
mRNA transcripts. When the gland becomes cancerous, the number of unique transcripts
decreases to approximately 15,000. The prostate expresses approximately 15% of the total
number of possible transcripts in the human genome.

64

Figure 3-1: Unique transcripts in the normal and cancerous prostate gland
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Genes of the human genome

Human genes were extracted from a collection of chromosomal files contained in the
Genbank resource at NCBI [54]. Genbank is a non-redundant collection of nucleotide sequences
submitted by researchers in the biomedical field. Even though the resource is maintained by the US
National Institute of Health, the database is synchronized daily with the European Molecular
Biology Laboratory (EMBL) nucleotide sequence database and the DNA Databank of Japan.
Genbank provides a comprehensive collection of all known genetic sequences. The database was
downloaded on March 2, 2008 from
ftp://ftp.ncbi.nih.gov/genbank/genomes/Eukaryotes/vertebrates_mammals/Homo_sapiens/GRCh37.
A PERL script was written to parse desired information from the flat format sequence file. The
information extracted from Genbank was used to create the genes table of the MAPI interface
(Table 3-7).
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Table 3-7: MAPI Human Genes Table
The genes table in the MAPI interface contains the reference sequence ID (Refseq), the gene
symbol, chromosome of the gene, start and end of the gene and a short description of the role of
the gene in the cell for all known human genes.
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Table 3-7: MAPI Human Genes Table
Genes
Refseq ID
Contig ID
Chromosome
Chromosomal start
Chromosomal end
Direction
Gene symbol
Description
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Tissue Specific MicroRNA Prediction

The potential benefit of tissue co-expression of microRNAs and their targets was
evaluated, the predictions of Diana Micro T 3.0 and Pictar were overlapped and a set of targets
from the union was generated. The list of predictions was compared to a list of genes that were
expressed in the prostate gland. This combination of prediction tools was chosen because the
union of the two datasets was proven to have the highest level of sensitivity. The tissue specific
predicted target list was labeled as the MAPI dataset. If consideration is not given to tissue coexpression, the unioned dataset was shown to offer users a near 52% sensitivity but the number
of predicted targets neared 400,000 (Table 2-1).
A plot similar to the plot in Figure 2-3 was created and amended to plot the sensitivity of
each prediction tool against the average number of predicted targets per microRNA molecule. In
order to measure the sensitivity of tissue specific target prediction, a subset of proven
interactions that show an expression level of at least 1 transcript per million in the prostate gland
was assembled and used as a comparison set. The methodology is similar to that described in
chapter 2. MicroRNA prediction tools were evaluated using the standardized set of prostate
specific interaction pairs. The sensitivity of nearly every prediction tool was increased with the
exception of Miranda because proven interactions that are not expressed in the prostate were
excluded from the comparison set (Figure 3-3). The sensitivity of Miranda actually decreased
slightly when considering tissue specificity. The MAPI dataset, assembled from the union of
PicTar and Diana MicroT 3.0 had an increased sensitivity and a lower number of predictions.
It appears that including tissue specification increases the sensitivity of prediction
algorithms and concurrently increases specificity. The benefit to microRNA researchers is that
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Figure 3-2: Comparison of microRNA prediction tools ranked by average number of
predictions per microRNA
The sensitivity of each microRNA prediction tool was evaluated and plotted against the average
number of predicted targets per microRNA molecule.
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Figure 3-2: Comparison of microRNA prediction tools ranked by average number of
predictions per microRNA
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3000

Figure 3-3: Comparison of microRNA prediction tools using tissue specific filtration
Considering tissue specific gene expression increases the sensitivity of all microRNA prediction
tools and decreases the average number of predicted targets per microRNA molecule. MAPI
predictions (union of Pictar and Diana Micro T 3.0) offer users the best balance between
sensitivity and specificity. 62% of all proven interactions are predicted by this combination of
prediction tools.
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Figure 3-3: Comparison of microRNA prediction tools using tissue specific filtration
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the end user is more likely to find an interaction if it exists and they will have a lower number of
potential targets to evaluate.
The dataset labeled as MAPI had a sensitivity of over 60%. The only group of predictions
that had a higher sensitivity was the dataset assembled by considering any target predicted by
any of the prediction tools (union of all tools). MAPI was able to achieve this level of sensitivity,
while only predicting 1000 possible targets per microRNA molecule. The dataset assembled from
all prediction tools predicted an average of 3800 potential targets per microRNA molecule. The
number of predicted targets per microRNA from MAPI may be more biologically relevant than
the number achieved by the union of all prediction tools. Previous researchers have suggested
that each microRNA may regulate up to 500 targets [12]. Inclusion of tissue specific
transcriptional profiles increases the accuracy of computational prediction methods of microRNA
target identification.
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Chapter 4
Identification of Potential Targets of Human MicroRNA-17-3p Using MAPI
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Identification of potential targets of HSA-miR-17-3p

It was discussed in chapter 1, that the level of human microRNA-17-3p varies in a cancer
cell progression model and decreases as the cell becomes more tumorigenic. MicroRNA 17-p
was more abundant in the normal, non-tumorigenic cell line (P69) and markedly decreased in the
highly tumorigenic, metastatic cell line (M12) but increased in its weakly tumorigenic variant F6
[24]. It is also known that in patient tumor samples, normal epithelial tissue expresses higher
levels of miR17-3p than tumor cells [21]. In fact, it was noted that as the Gleason score of cancer
increases, there is a negative correlation to the level of miR-17-3p. That is as the cancer becomes
less differentiated and more aggressive, the level of miR-17-3p declines. These observations
prove that microRNA-17-3p functions as a tumor suppressor in the prostate gland.
Previous to the start of this work, it was shown that microRNA-17-3p regulates levels of
vimentin, an intermediate filament protein [22]. It is hypothesized that most microRNAs
regulate many targets. In order to determine other potential targets of miR-17-3p, we used MAPI
described in Chapter 3. Priority was given to targets of human microRNA-17-3p that are
expressed in the prostate gland and proven to be implicated in any form of human cancer (Table
4-1). Our search revealed two potential targets, insulin growth factor receptor 1 (IGF1R), and the
Yamaguchi sarcoma viral oncogene homolog 1 (YES1). Table 4-2 describes the potential targets
of microRNA-17-3p.
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Table 4-1: MAPI Search Parameters for Tumorigenic Targets of microRNA-17-3p
Version 1.0 of the MicroRNA Annotation and Prediction Interface was queried to identify
potential targets of the tumor suppressing microRNA-17-3p that are expressed in the prostate
gland. The query options utilized are described in the table.
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Table 4-1: MAPI Search Parameters for Tumorigenic Targets of microRNA-17-3p
Field

Parameter

MicroRNA

Human microRNA-17-3p

Tools

PicTar and Diana Micro T 3.0 union

Cancer related

Yes

Tissue

Prostate

Health State

Normal
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Table 4-2: Potential Targets of Human microRNA-17-3p
Potential targets of miR17-3p expressed in the prostate gland and implicated in cancer. YES1 is a
member of the src family and possesses non-receptor tyrosine kinase activity [55]. IGF1R is a
trans membrane receptor tyrosine kinase implicated in many forms of cancer [56].
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Table 4-2: Potential Targets of Human MicroRNA-17-3p
Gene

Refseq ID

Chromosome/

Function

cytogenetic band
Yamaguchi Sarcoma Viral

NM_005433

18p11

Homolog 1(Yes1)[13]
Insulin Growth Factor

src family member/
non-receptor tyrosine kinase

NM_00875

15q26

Receptor 1 (IGF1R)[13]

Binds insulin growth factor and
results in hypertrophy of cells
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Structural Analysis of IGF1R and miR-17-3p Dimer

The 3’UTR of the insulin growth factor receptor gene and the sequence of human
microRNA-17-3p were submitted to RNAhybrid, a tool for the determination of minimum free
energy hybridization of long and short RNA molecules [48]. miR-17-3p and IGF1R are able to
achieve dimerization at -31.7 kcal/mol. It is generally thought that true interactions between
microRNA and target genes will have a delta G of less than -25.0 kcal/mol. The predicted
structure has perfect seed region binding with bases 2-8 of the microRNA bound to the 3’ UTR
of IGF1R. The eighth position has a G:U wobble but all other bases of the seed participate in
canonical Watson Crick base pair interactions. Two base pairs of the microRNA are unable to
bind to the gene and loop out. There is significant 3’ compensatory loop interactions of the
microRNA. The predicted dimer structure appears to satisfy all of the rules identified for
microRNA/ gene binding. (Figure 4-1a).

Multiple Sequence Alignment of IGF1R 3’ UTRs

3’ untranslated regions of the IGF1R gene were downloaded using the UCSC genome
browser [57]. The sequences were compiled into a single fasta formatted file using PERL and
submitted to the ClustalX program locally [58]. Figure 4-1b shows the regions of the alignment
that correspond to the predicted binding site of IGF1R. It is generally thought that cross species
conservation of nucleotides results from selective pressures to retain a given sequence and
mutations in highly conserved regions are thought to be fatal. The majority of the 3’ untranslated
region of a gene is not conserved across multiple species, so regions of conservation have been
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obviously retained for functional purposes. The predicted binding site of miR-17-3p is highly
conserved across the species suggesting that this region of the 3’ UTR may be involved in an
interaction with microRNA-17-3p.
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Figure 4-1: Multiple Sequence Alignment of IGF1R UTR and Predicted Structure
A. RNAhybrid predicted structure of microRNA-17-3p and the 3’ UTR of insulin growth
factor receptor gene [48]. The predicted minimum free energy is -31.7 kcal/ mol. The
maximum free energy of a true target is generally thought to be -25.0 kcal/ mol. The
overall structure adheres to all known “rules” observed in previous proven targets.
B. IGF1R sequences from human, mouse, rat, dog, and chimpanzee were aligned using
Clustal X [58]. With the exception of the second base in mice and rats, all bases of the
seed region are perfectly conserved across all species. Much of the 3’ UTR not shown in
this figure is not conserved. This implies a selective pressure for this region of the gene.
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Figure 4-1: Multiple Sequence Alignment of IGF1R UTR and Predicted Structure
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Structural Analysis of YES1 and miR-17-3p

The sequence of the Yamaguchi Sarcoma Virus Oncogene Homolog was obtained from
NCBI and submitted to the RNAhybrid program, along with the sequence of human microRNA17-3p [48]. The predicted minimum free energy of dimer formation is -22.5 kcal/mol. Bases 2-8
of the seed region are predicted to bind to the 3’ UTR of the gene, with a G:U wobble at position
seven of the microRNA. There is a large loop of the UTR and a region of the microRNA that is
not predicted to bind to the gene. Figure 4-2 shows the predicted structure of the miR and the
UTR of the YES1 gene. The predicted structure did not support the prediction of YES1 as a
potential target and it was not investigated further.

Insulin Growth Factor Receptor 1

The insulin growth factor receptor 1 gene imparts a survival advantage, an anchorage
independent growth advantage to cells and protects cells from apoptosis [56, 59]. Cells that
express higher levels of IGF1R are shown to be more tumorigenic and metastatic. It is
hypothesized that increased levels of IGF1R lead to a transformed phenotype that imparts an
oncogenic potential to the cell.
Tissue samples extracted from formalin-fixed, paraffin embedded tissue obtained from a
fine needle biopsy showed higher protein and mRNA levels of IGF1R in primary prostate cancer
compared to benign prostatic epithelium [59]. Levels of insulin growth factor receptor 1 were
also shown to increase in the metastatic sites of prostate cancer. Metastasis is accomplished
because metastasizing cells must detach themselves from other cells in the tissue and mobilize
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Figure 4-2: Predicted Structure of miR-17-3p and YES1
RNAhybrid predicted structure of dimer formation between microRNA-17-3p and the 3’ UTR of
YES1 [48].
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Figure 4-2: Predicted Structure of miR-17-3p and YES1
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themselves. Vimentin has been shown to correlate with an increased ability of cells to be motile
and invasive [60]. IGF1R potentially causes an upregulation of extracellular proteases in the
prostate, imparting an ability of cells to detach from their neighbors [61]. Because of the
structural prediction, sequence conservation and functional significance, further validation of
IGF1R was undertaken.

Validation of miR-17-3p and IGF1R Interaction

In order to validate the regulation of insulin growth factor receptor 1 levels in the
prostate, protein levels were measured in a prostate cancer cell line [24]. Two sublines were
chosen for comparison of protein levels. The first is a highly tumorigenic, metastatic cell line
stably transformed with a plasmid that expresses a non-targeting RNA molecule (M12 +NTC).
This cell line serves as our negative control. A second set of highly tumorigenic, metastatic cells
was stably transformed with a plasmid that expresses a functional copy of microRNA-17-3p
(M12 + miR17-3p) [22]. This cell line is our experimental model.

Cell Culture Methods

All cells were grown at 37° C in RPMI 1640 growth media containing L-glutamine
obtained from Sigma-Aldrich and supplemented with 5% fetal bovine serum, 5 μg/ml insulin, 5
μg/ml transferring, 5 ng/ml selenious acid, (ITS from Collaborative Research Bedford,MA).
Gentamycin (0.05 mg/ml) was added to inhibit bacterial contamination of culture. Cells
containing the integrated plasmids were selected by growth in puramycin. All tissue culture cells
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were grown in 250 ml T75 flasks and split when confluent. Cells were pelleted after trypsin
digestion by centrifugation at 5000 rpm for five minutes. Cells pellets were washed in 1X PBS
buffer and re-centrifuged at 5000 rpm for five additional minutes. Following pelleting of the
cells, cells were flash frozen in liquid nitrogen and stored at -80 ° C.

Western Blot Analysis
Cell pellets were thawed on ice and re-suspended in 200 - 400 microliters of 4% SDS in
PBS after thawing. Cell lysates were prepared by sonication of cell suspension for five minutes.
Following sonication, cellular debris was removed after dilution of lysate in one volume of PBS
buffer and centrifugation at 10,000 rpm for five additional minutes. Proteins (50 mg) were
separated by electrophoresis on a BioRad SDS denaturing 4-14% Tris-HCl gradient gel at 120
mV for 1.5 hours.
Separated proteins were transferred to a nitrocellulose membrane and non-specific
interactions were minimized by blocking the membrane in 3% powdered milk dissolved in TBST
buffer. IGF1R proteins were visualized using IGF-I receptor beta antibody from Cell Signaling
Technology and a secondary anti-rabbit antibody.
Figure 4-3 shows the results of the western blot analysis of the M12 + NTC and M12 +
miR-17-3p cell lines. Actin was used as an internal control to verify consistency of protein loads.
Vimentin levels were also analyzed to ensure that the plasmid transcribing miR-17-3p was
functioning, as it is known that miR-17-3p targets vimentin. Protein levels of IGF1R were
significantly higher in the M12 + NTC cell line as compared to the levels in the M12 + miR-173p cell line. The level of actin was consistent across both cell lines and the levels of vimentin
exhibited the expected decrease in expression confirming the increased level of miR-17-3p in the
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stably transformed M12+miR-17-3p cell line. The decrease in IGF1R levels dependent on miR17-3p confirms that IGF1R mRNA is targeted by miR-17-3p.
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Figure 4-3: Western Blot Analysis of IGF1R Protein Levels
Whole cell extracts were subjected to Western blot analysis with antibody to IGF1R, actin, or
vimentin in M12 cells with restored expression of miR-17-3p (M12+ miR-17-3p) compared to
M12 cells expressing a negative non-targeting RNA control (M12+NTC). Levles of actin are
consistent in both lanes of the western blot, proving that the load of protein is similar in both
lanes of the gradient gel. Vimentin levels were analyzed as a positive control, as it has been
previously shown that miR-17-3p targets vimentin [22].
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Figure 4-3: Western Blot Analysis of IGF1R Protein Levels
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Conclusions

Prostate cancer is a significant problem for men in the United States and across the world.
MicroRNA proteins are post-transcriptional regulators of protein products that have been shown
to be involved in numerous cellular processes. MicroRNA dysregulation has been shown to lead
to the development of several forms of human cancer. Human microRNA-17-3p has been shown
to be differentially regulated in primary tumors of the prostate and decreases as the Gleason
score of the tumor increases.
miR-17-3p has been shown to target the intermediate filament protein vimentin. It is
hypothesized that most microRNAs target more than one protein. A bioinformatics approach was
undertaken to elucidate further putative targets of miR-17-3p. A unique comprehensive
microRNA target prediction tool was designed that harnesses the information inherent in many
freely available databases and combines them into a single resource. This comprehensive
database was used to identify other potential targets of miR-17-3p. IGF1R was identified as a
potential target of the microRNA, which was previously shown to be differentially regulated in
prostate cancer. Prostate cancer cell lines were utilized to verify regulation of IGF1R by miR-173p. Levels of IGF1R protein varied between the cell lines and was lower in the cell line
expressing microRNA-17-3p. Based on these experiments, it does indeed appear as if
microRNA-17-3p regulated the levels of insulin growth factor receptor and the MAPI interface
was instrumental in identifying this new relevant target for miR-17-3p.
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